Sumoylation of hypoxia inducible factor-1α and its significance in cancer

Abstract

Hypoxia-inducible factor-1 (HIF-1) is a key heterodimeric transcription factor for the cellular adaptive response to hypoxia, a common feature of the microenvironment in solid tumors. The transcriptional activity, protein stabilization, protein-protein interactions and cellular localization of HIF-1, an oxygen-sensitive subunit of HIF-1, are mainly modulated by various post-translational modifications. Recently, we reported that polycomb chromobox 4 (Cbx4) governs the transcriptional activity of HIF-1α by enhancing its sumoylation at K391 and K477, through which Cbx4 potentiates angiogenesis of hepatocellular carcinoma. This review summarizes the current knowledge of HIF-1 sumoylation and its roles in the pathogenesis of cancer.

Fibrogenic/Angiogenic Linker for Non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C genotype 4 patients

“…the fenestrae were lost. Then, the disease is progressed and hypoxia was developed [33]. These mechanisms requiring the participation of pro-inflammatory cytokines and growth factors [34]; including VEGF.…”

CBX4 Expression and AFB1-Related Liver Cancer Prognosis

“…Because several previous studies have exhibited that CBX4 can progress tumorigenesis via several signal pathways, including CBX4/HIF-1α/VEGF pathway [20,25,26,34], CBX4/ HDAC3/Runx2 pathway [21], CBX4/P63 pathway [22], CBX4/miR-195 pathway [40], CBX4/ CtIP pathway [41], and CBX4/P53 pathway [42,43], here we investigated the effects of CXB4 expression on HCC outcome. We not only found that increasing CBX4 expression in the cancerous tissues is a poor prognostic biomarker for HCC, but this increasing expression is associated with clinicopathological features such as tumor size, tumor stage, and angiogenesis.…”

“…Functionally, CBX4 involves in PRC1-regulated transcription repression and post-translation modification [19][20][21][22]. Recently, increasing evidence has exhibited that the dysregulation of this gene may affect the carcinogenic process of some tumors such as HCC, colorectal cancer, breast cancer, and so on, and may be a significant prognostic biomarker [19,21,[23][24][25][26][27][28][29]. However, it is not clear whether CBX4 modify the prognosis of AFB1-related HCC.…”

NK cell-based cancer immunotherapy: from basic biology to clinical application

“…Several general mechanisms are suggested including inaccessibility of NK cells to the tumor due to defective vascularization, deficient expression of adhesion molecules or activating receptors on NK cells, high expression of MHC class I on tumor cells, resistance to the Fas-or perforin-mediated apoptosis and secretion of immunosuppressive factors such as IL-10 or TGF- by tumors [1,66]. Therefore, approaches to improve cytotoxicity or restore immune system are necessary to effectively enhance cancer immunotherapy.…”